Okta (OKTA) stock has delivered one of the more striking moves in software this year. Its shares have climbed 93.8% over the past three months. That sharp re-rating has left the stock trading only 2.6% below its recent peak, even as investors continue to debate the durability of the next growth phase.
The latest spark came on Aug. 12, when Citizens JMP Securities upgraded Okta to "Market Outperform". With Okta scheduled to report fiscal second-quarter results after the close on Aug. 26, the upgrade lands at a moment when the market is especially focused on whether accelerating demand for securing AI agents can sustain the rally.
A $20 Billion Reason Why Intel Stock Is in Focus
Mark Cuban Says If You Win The Lottery, Don't Take The Lump Sum — And Tell People Who Ask for Money No, But 'Be Nice. No One Likes a Mean Billionaire'
Jefferies' Latest Warning on Palantir Sends Clear Message: Stay Cautious on PLTR Stock

#securities #outperform #reason

Five Below (FIVE) shares extended gains on Thursday after Jefferies issued a bullish note in favor of the Philadelphia-headquartered chain of discount retail stores. ***** yst Randal Konik upgraded FIVE this morning and raised his price target to $350, indicating potential upside of more than 40% from current levels.
Konik's research note arrives at a time when Five Below stock is already on an uptrend, currently up more than 35% versus its July low.
A $20 Billion Reason Why Intel Stock Is in Focus
Marvell Technology (MRVL) Stock Might Offer a Quick Bounce Before Earnings
Mark Cuban Says If You Win The Lottery, Don't Take The Lump Sum — And Tell People Who Ask for Money No, But 'Be Nice. No One Likes a Mean Billionaire'

#jefferies #konik

Jefferies initiated AEHR with a Buy rating and $175 target, calling its model conservative and excluding memory wins and AI customer upside.
COHU gained 151% and TER rose 112% year to date as AI chip complexity drives demand for more intensive semiconductor testing.
AEHR carries extreme valuation risk with a beta of 3.09, a recent 43% YoY revenue drop, and steady CEO and CFO insider selling.
Don't wait: the ****** yst who called NVIDIA in 2010 just revealed his top 10 AI stocks. See the full list FREE now.
Shares of Aehr Test Systems (NASDAQ:AEHR) are up roughly 8% in Friday midday, after a fresh Wall Street initiation lit another fire under one of 2026's most explosive small caps. The move extends a year-to-date advance of 510.7% and pushes the stock through its 52-week high of $133.35.

#date #free

Apple (NASDAQ:AAPL) shares are in the red today amid reports that rising memory costs could result in higher prices for the iPhone 18, while a Jefferies report indicated disappointing prospects for an all-glass iPhone. However, Gene Munster, managing partner at Deepwater ***** et Management, said in a recent program on CNBC that he still feels good about Apple and remains bullish on the stock.
Munster believes a potential increase in iPhone prices could actually help boost Apple's revenue growth, with limited impact on demand. At the core of his argument is his expectation of a strong upgrade cycle for Apple's iPhone business, which he believes could drive higher sales over the next several quarters. He also sees a broader consumer hardware upgrade cycle driven by personalized AI beginning around 2027, which he believes could create another major growth opportunity for Apple.
"There's going to be a massive upgrade cycle around consumer hardware," Munster said. "That's probably going to start 27 mid to late 27 and probably go for a few years. And that's based on personalized AI. That's going to do inference on device that's going to benefit Apple, that's going to benefit other hardware makers. And so when you put this together, I think shares are undervalued. And I think we're going to see a strong next 12 months."
Not all is good for Apple. The stock trades at around 35x forward earnings while growth is decelerating. Revenue growth is expected to fall back to single digits in FY27 once the current upgrade cycle matures. Q4 guidance already shows the slowdown starting, with revenue growth of 9% to 11% versus 16% in Q3. That makes Apple the slowest grower in the Magnificent Seven outside Tesla, yet it trades at the highest multiple. Meta grows over 20% at roughly 19x forward earnings. Alphabet trades at 18x. Amazon at 23x. Microsoft at 25x. Apple is at 35x.
Apple is losing the AI race and outsourcing its way through it. The new Siri runs on Google's Gemini model. Apple reportedly pays around $1 billion a year for it. Microsoft, Alphabet, and Amazon have ways to monetize their cloud platforms. Apple is renting intelligence from a direct competitor and has no clear way to make money off it.

#going #upgrade #around #believes

Five golds to be won on day two at Birmingham's Alexander Stadium - watch live on BBC One (UK only)
LIVE: Greatt Britain's Romell Glave and Jeremiah Azu win gold and silver in men's 100m as Italy's Marcell Jacobs pulls up halfway through
Netherlands' Nadine Vesser wins women's 100m hurdles by 0.001 seconds, GB's Marcia Sey finishes eighth
Greece's Miltiadis Tentoglou wins fourth men's long jump **** le
Local favourite Matthew Hudson-Smith second in his 400m semi-final, but Charlie Dobson and Ben Jefferies go out

#five #greatt #romell #jeremiah

Five golds to be won on day two of European Championships at Birmingham's Alexander Stadium - watch live on BBC TV (UK only)
LIVE: GB's Hannah Nuttall fifth in women's 5,000m final won by Italy's Nadia Battocletti
20:32: Men's 100m semi-finals featuring Italy's two-time champion Lamont Marcell Jacobs and GB's Romell Glave, Jeremiah Azu and Louie Hinchliffe
21:00: Men's 400m semi-finals with home favourite Matthew Hudson-Smith, Charlie Dobson and Ben Jefferies
21:30: Women's 100m hurdles final

#finals #five #stadium

AstraZeneca and Bristol Myers Squibb never held merger discussions and are not in talks now, a senior source close to the matter told Reuters on Wednesday.
"There is no deal between AstraZeneca and BMS. There never was a deal to be done, and there are no discussions between the companies," the source said, under the cover of anonymity. Neither company offered a comment when contacted by Reuters.
The denial came days after reports that the two pharmaceutical companies had been in preliminary discussions about a combination that could have created a company worth close to $400 billion. The Financial Times first reported the story. Reuters, which broke the Sunday story on the preliminary talks, noted at the time that it could not confirm whether those conversations were still active.
AstraZeneca shares dropped roughly 9% in the wake of the deal reports, while Bristol Myers Squibb shares weathered the news with relatively little movement.
When the merger reports first surfaced, as covered earlier this week, AstraZeneca stock tumbled as much as 7% on Monday. Bristol Myers Squibb stock rose 6% in U.S. premarket trading. **** ysts at Jefferies questioned the strategic rationale, writing that AstraZeneca was a company that did not need "financial engineering." Citi **** ysts called the reported talks a "surprise" given AstraZeneca's pipeline, according to CNBC.

#astrazeneca #bristol #reuters #reports

Ford Motor Company (F) has failed to attract many Wall Street players for most of the past year. Now one firm has decided to reconsider its stance on it.
Jefferies upgraded Ford to buy from hold on Monday, July 27, and raised its price target to $17.50 from $14.50.
The call landed one day before Ford reported its second-quarter results, and Jefferies' new target sat roughly 21% above where the stock traded early Monday, near $14.46.
The upgrade matters because Jefferies did not wait for the numbers to confirm the thesis. It bet that Ford's second quarter would mark the low point for margins and volume before things improve.
For anyone holding Ford, or watching it, the question was simple: Did the setup justify buying before the print? The July 28 report gave the first answer.

#company #wall

The AI buildout has resulted in an unanticipated casualty distant from Silicon Valley: telecom equipment manufacturers, who now compete with hyperscalers for the same memory chips. Three major companies, SK Hynix, Samsung, and Micron, control more than 95% of worldwide DRAM production, and as AI data centers use an increasing share of that output, memory chips used in telecom base stations become scarcer and more expensive as a direct result. That is the mechanism behind Telefonaktiebolaget LM Ericsson (NASDAQ:ERIC)'s worst single-day stock reaction in nearly three years.
The company's shares plunged about 12% on July 14, reaching their lowest level since February, after Ericsson warned that growing component costs, particularly memory chips, will affect margins in the future. Looking into Ericsson's Q2 2026 results, the market's harsh reaction was more about forward guidance rather than a breakdown in existing operational execution. Adjusted EPS was SEK 1.22 (~$0.13), which was in line with market expectations. Adjusted gross margin increased to 48.4%, a two-percentage-point year-over-year rise after normalizing for a prior-period IPR licensing settlement. Meanwhile, reported net sales declined 6% to SEK 52.7 billion ($5.62 billion), missing the SEK 53.71 billion forecast, while organic sales excluding currency and one-offs remained essentially flat.
What worried investors was guidance and cash flow, not the print itself. Free cash flow before M&A fell to SEK 0.4 billion from SEK 2.6 billion a year ago, owing to increased inventories being accumulated ahead of scheduled third-quarter deliveries. Management forecasted Q3 Networks adjusted gross margin to a range of 48% to 50%, a slight decrease from Q2 levels, noting a higher share of lower-margin network rollout projects and component inflation developing "gradually" during the second half of 2026 and into 2027.
Jefferies, which rated the stock at a Hold with a target price of 98 Kronor, framed the sales miss as being centered primarily on delayed India deliveries within the Networks division as opposed to broad-based demand weakness, and noted Ericsson is forecasting a stronger-than-seasonal third quarter as those delayed deliveries arrive.
The sudden selloff has generated an attractive valuation gap for long-term investors. Telefonaktiebolaget LM Ericsson (NASDAQ:ERIC) is currently trading at a 14.45x forward P/E multiple, representing a significant discount to key infrastructure rivals such as Nokia, which trade on similar 5G-cycle and edge-connectivity theses. The market's knee-jerk reaction appears to regard temporary component inflation as a permanent weakening of Ericsson's earnings potential, resulting in a clear disparity between price and underlying value.

#billion #adjusted #memory

Digital advertising spending in 2026 is expected to expand unevenly. According to the IAB's 2026 Outlook Study, overall US ad spend is projected to grow by 9.5% this year, with social media advertising growing 14.6%, well outperforming the broader industry. However, growth is not evenly spread across advertiser sizes, with larger consumer firms lowering marketing expenditure as one of the fastest ways to maintain profitability amid wary consumers and narrowing margins.
That's the backdrop in which Reddit, Inc. (NYSE:RDDT) is placing a significant bet: while the biggest social platforms compete for the same narrowing pool of massive brand advertisers, Reddit is slowly opening the door to small and medium-sized businesses that couldn't previously manage the cost of creating a personalized ad campaign.
That shift became clear when Reddit, Inc. (NYSE:RDDT) released a beta version of Reddit Community Intelligence on July 10, an AI-powered, free-form ad generator that provides advertisers with AI-generated creative recommendations customized to certain communities instead of forcing them to start from scratch. The tool is deliberately designed to make campaign creation easier for advertisers targeting community-specific audiences, which have traditionally found platform advertising too resource-intensive to bother with.
Wall Street research desks realized the structural significance of the self-service shift. On July 13, Citizens ***** yst Andrew Boone confirmed his Market Outperform rating and $240 price target for Reddit, Inc. (NYSE:RDDT), citing automated self-service technologies as a key revenue driver. Boone emphasized that lowering friction for smaller advertisers enables Reddit to capture previously untapped performance budgets, resulting in long-term, lower-funnel revenue streams.
Crucially, Reddit's advertising momentum was accelerating even before the Community Intelligence tool shipped. On July 10, Jefferies, drawing on conversations with agencies, added that Reddit, Inc. (NYSE:RDDT) continued to gain share in social media advertising through the second quarter. Agencies said that this was due to the platform's large and growing audience, growing reach, and more personalized targeting, a read that preceded the Community Intelligence launch and shows the platform was already winning before the tool even shipped.

#rddt #advertising #growing

After trying Meta Platforms' (META) AI glasses lineup, Wall Street ****** ysts have turned bullish on the company's hardware ambitions, a possible change of heart considering how much money Meta has lost on Reality Labs and virtual reality (VR). Improved cameras, comfortability, and enhanced audio were the main drivers of the positive reception. Jefferies ****** ysts believe the glasses could become a real new growth driver for the company after testing the Ray-Ban Meta Gen2, Oakley Meta, and Ray-Ban Display. But what caught my attention was not hidden in the product notes — it was in the price tags of $379, $499, and $799, respectively. This pricing points to a long-term strategy designed to generate repeat purchases over years, not a single sale.
Starting with the entry point, the Ray-Ban Meta Gen2 is only voice-first, camera-equipped, and with no display. Next, the Oakley Meta at $499 pushes into a sportier niche at a slightly higher price. Finally, at $799, the Ray-Ban Display with Neural band is Meta's top-of-the-line model — the only one with an actual screen and gesture control. This product lineup clearly shows something that Meta is trying to build on: Pulling customers up the ladder over successive purchases rather than selling them a single product once.
Ahead of Microsoft Earnings, Here's What Barchart Data Says Comes Next for MSFT Stock
Nasdaq Futures Plunge as Chip Selloff Rages On, FOMC Meeting and Earnings on Tap
Broadcom Leads 3 AI Stocks Quietly Raising Their Dividends, One by 161%

#product #next #earnings

Two Detroit automakers jumped Monday morning on positive ****** yst news. Jefferies upgraded both General Motors and Ford to buy ratings, from hold.
The investment firm raised General Motors' price target to $99 from $90; and Ford to $17.50, up from $14.50, according to theFly.com. The price targets imply a 12-month upside of 17% for GM and 21% for Ford, relative to where shares traded Monday morning.
The ****** yst action for both companies follows an extended period of hold ratings, and comes after both automakers in December incurred huge, multibillion write-offs related to a series of electric vehicle investments that didn't pan out.
Ford stock rose as much as 3% on Monday's news as it continues to hug its 50-day line, according to MarketSurge. Meanwhile, General Motors' 3.5% gain pushed it briefly above a buy point of 85.41 as it tinkers with a breakout from a flat base. Over the last 12 months, General Motors (GM) is up just under 60%. Ford (F) advanced roughly 28%.

#ford #automakers

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly.

Top 5 Upgrades:
Jefferies upgraded Verisk ****** ytics (VRSK) to Buy from Hold with a price target of $235, up from $192. Verisk's Q1 report "likely marks a trough," with its organic growth improving to 5% year-over-year in Q2, and accelerating further in the second half of 2026, the firm tells investors in a research note.
Morgan Stanley upgraded PayPay (PAYP) to Overweight from Equal Weight with a price target of $23, down from $24. The firm says that while the company's near-term catalysts remain limited, the stock's risk/reward suggests the upside potential outweighs downside risk.
Wolfe Research upgraded AT&T (T) to Outperform from Peer Perform with a $29 price target. The company's Q2 brought "stable and better than expected" unit economics, the firm tells investors in a research note.
KeyBanc upgraded Ameren (AEE) to Overweight from Sector Weight with a $122 price target. The firm believes increasing visibility around incremental load growth could position Ameren for a "meaningful earnings growth revision as early as this fall."

#Research #price #investors #Growth

Twilio Inc (NYSE:TWLO) is expected to deliver second quarter results that exceed expectations on revenue and operating income, with investors likely to focus on whether the communications software company's gross profit growth can remain in the mid-teens during the second half of the year, according to Jefferies ******* ysts.
Ahead of Twilio's August 6 earnings release, Jefferies wrote that it expects the company to post revenue and operating income above expectations, although it does not anticipate the same degree of outperformance as in the first quarter.
The firm added that while business fundamentals remain strong, the stock's premium valuation and heavy investor positioning could limit upside unless Twilio significantly raises its outlook.
Jefferies forecasts second-quarter revenue of $1.427 billion, up 16% year over year and broadly in line with consensus expectations and the company's guidance range of $1.42 billion to $1.43 billion.
The firm expects gross profit of $684 million, implying a gross margin of 47.9%, compared with consensus expectations of $690 million and a 48.3% margin. It projects operating income of $255 million, or a 17.9% operating margin, and earnings per share of $1.30, versus Wall Street expectations of $258 million in operating income and EPS of $1.33.

#expectations

Advanced Micro Devices (AMD) hosts its Advancing AI event in San Francisco on July 22-3, and Jefferies expects a busy day. ******* yst Blayne Curtis, who has a "Buy" rating and a $615 price target, thinks AMD will raise its estimate of the total market for its processors past $200 billion. He expects fresh details on the MI500 chips due after the current generation. The part investors will be keen on watching is the customer list. The ******* yst believes Microsoft (MSFT) is signed up for the MI450. There are also growing talks of a deal with Anthropic, which has reportedly been hiring engineers familiar with AMD's software.
The reason a new customer matters so much comes down to how AMD won the last two. To land OpenAI and Meta Platforms (META), each committing to six gigawatts of chips, AMD handed both companies warrants to buy up to 160 million shares. Combined, AMD has promised away about a fifth of itself to secure those orders.
Huge, Unusual Intel Options Volume Today Ahead of Earnings This Week
Intel Stock Is Down, But Put Premiums are High - Put Short Sellers Love the High Yields
The Number Tesla Stock Bulls Are Really Waiting for This Earnings Season Has Nothing to Do With Cars

#earnings #customer

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter.
Novartis said second-quarter sales inched upward, beating **** yst expectations for a decline as demand for newer products helped offset generic competition for its former top-selling heart medication Entresto.
At constant exchange rates, net sales increased 1% to $14.4 billion, Novartis said Tuesday. That beat the consensus estimate of about $13.7 billion, Jefferies **** yst Michael Leuchten wrote in a note to clients. Core operating income reached $5.94 billion, topping the consensus estimate of $5.31 billion. Leuchten had expected core operating income of $5.16 billion on sales of $13.8 billion.
The Swiss drugmaker highlighted increases of more than 30% for "priority brands" including Kisqali, Kesimpta, Scemblix, Pluvicto and Leqvio. Revenue from Entresto plunged by half to $1.18 billion in the period, moving the drug down to fourth place on the list of Novartis' most lucrative products.
Already buffeted by Entresto losses in the U.S., Novartis is looking ahead to one of the most daunting patent cliffs in the pharmaceutical industry over the next five years, affecting all four of its top-selling medicines in the second quarter. Entresto is set to lose exclusivity in Europe in 2028. After that, U.S. patent expirations follow for its biggest moneymaker, Cosentyx, in 2029 and both Kesimpta and Kisqali in 2031.

#billion #biopharma #dive

Dan Ives logs into the Zoom call in a loud, tropical shirt, the word "Margaritaville" splashed across the chest. He has spent the better part of 25 years as one of Wall Street's most recognizable tech bulls — a go-to voice on everything from Apple to Nvidia, a prolific note-writer who repeated the phrase "fourth industrial revolution" and has been telling investors, through every dip and correction, that they're still in the early innings. He has made a lot of people a lot of money by being consistently, loudly optimistic about technology stocks.
Now he is doing what he spent a decade and a half telling everyone else to do.
"Look, I'm an example of what I've preached over the years that AI will ultimately create more jobs than what it takes away," he told me in an interview, several weeks after leaving Wedbush Securities to launch Yorkville Ives, what he calls a "modern merchant bank" with Yorkville Securities. "If it wasn't for the AI revolution and it wasn't for this period … I couldn't do something like this."
That's the short version of what happened. The longer version, Ives told Fortune, is that after 25 years covering other people's companies, he realized he had never actually built one himself — and he wanted to. "As an ***** yst I always talk about companies, whether good or bad, what they've done. But I've never built anything," he said. He has helped institutional investors make money and CEOs shape narratives, he added, but he felt the itch. "I wanted to get off the treadmill and actually build something myself."
The first question, though, is just what he is building, actually. Ives said he traces the merchant bank concept back to Thomas Weisel and the early Jefferies era of the 1990s — outfits that didn't just publish research but put their own capital into transactions. "A lot of banks … they won't put their own money [in], they don't have the capital," he said. "That to me is really the key in terms of the difference with a merchant bank versus a typical investment bank."

Sable Offshore Corp. (NYSE:SOC) is one of the 10 best stocks under $10 that could triple.
On July 6, Lloyd Byrne from Jefferies reduced Sable Offshore Corp.'s (NYSE:SOC) price target from $24 to $11. Despite such a huge downward adjustment, the price target still results in an upside potential of over 180%.
Pixabay/Public Domain
The ****** yst maintained a Buy rating on the stock despite some recent challenges, such as the dilution for current equity holders caused by the recent convertible notes offering. The offering was executed amid the company's failure to attain government support.
Earlier on July 1, Sable Offshore Corp. (NYSE:SOC) shared details around the company's recent public offerings. These involved 32,467,533 common shares, priced at $3.08 per share, and the issuance of 6.5% convertible senior notes with a $300 million principal amount due in 2031.

EQT Corporation (NYSE:EQT) is one of the 8 Worst Blue Chip Stocks to Buy Now.
On July 8, 2026, UBS lowered the firm's price target on EQT Corporation (NYSE:EQT) to $73 from $74 previously and kept a Buy rating on the shares.
On July 2, Jefferies **** yst Lloyd Byrne lowered the firm's price target on EQT Corporation (NYSE:EQT) to $75 from $77 and kept a Buy rating on the shares as part of a Q2 preview. Byrne said Jefferies expects EQT to post Q2 EBITDA of $1.13B, just below the consensus of $1.19B.
On June 30, Freedom Broker initiated coverage of EQT Corporation (NYSE:EQT) with a Buy rating and $79 price target on the shares. The firm said EQT is the largest U.S. natural gas producer and is positioned to benefit from improving natural gas market fundamentals.
EQT Corporation (NYSE:EQT) engages in the exploration, production, gathering, and transmission of hydrocarbons and natural gas.

Sable Offshore Corp. (NYSE:SOC) is one of the 10 best stocks under $10 that could triple.
On July 6, Lloyd Byrne from Jefferies reduced Sable Offshore Corp.'s (NYSE:SOC) price target from $24 to $11. Despite such a huge downward adjustment, the price target still results in an upside potential of over 180%.
Pixabay/Public Domain
The ****** yst maintained a Buy rating on the stock despite some recent challenges, such as the dilution for current equity holders caused by the recent convertible notes offering. The offering was executed amid the company's failure to attain government support.
Earlier on July 1, Sable Offshore Corp. (NYSE:SOC) shared details around the company's recent public offerings. These involved 32,467,533 common shares, priced at $3.08 per share, and the issuance of 6.5% convertible senior notes with a $300 million principal amount due in 2031.

Leidos Holdings, Inc. (NYSE:LDOS) is one of the Best ***** e Technology Stocks to Buy Now. Recently, on July 1, Jefferies lowered the price target on Leidos Holdings, Inc. (NYSE:LDOS) from $140 to $110, while maintaining a Hold rating on the shares. On the same day, Citi also lowered the price target on the stock from $178 to $138 and maintained a Buy rating.
Jefferies noted that the reduced price target is based on the expectation that the fiscal Q2 2026 earnings will mark the low point for the year. The firm expects flat organic revenue growth due to a 3% decline in the Health unit. For the full year, the firm expects 3% organic growth for the company.
On the other hand, Citi's rating came as part of a broader update to estimates and price targets across the aerospace and defense sector ahead of Q2 earnings. Citi expects aerospace companies to post "big beats" with moderate guidance raises this quarter. The firm noted that defense names are less likely to post big beats. Moreover, Citi sees more room for share price upside in defense names, given the group's compressed valuation multiples.
Leidos Holdings Inc. (NYSE:LDOS), along with its subsidiaries, offers services and solutions for government and commercial customers in the U.S. The company operates through segments including National Security & Digital, Health & Civil, Commercial & International, and Defense Systems.
While we acknowledge the potential of LDOS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Western Alliance Bancorporation (NYSE:WAL) is one of the top bank stocks to buy now according to **** ysts. Wall Street has a consensus Moderate Buy rating on Western Alliance Bancorporation (NYSE:WAL). A total of 41 hedge funds have positions in the stock.
On July 6, Western Alliance Bank, the primary subsidiary of Western Alliance Bancorporation, announced financing for Marble Manor Phase I, a 138‑unit mixed‑income housing project northwest of downtown Las Vegas. The package includes $31 million in tax‑exempt construction bonds, $2 million in taxable bonds, and $19.46 million in tax‑exempt permanent bonds, with R4 Capital Funding managing construction and permanent **** ets.
The development will feature five residential buildings with one‑ to five‑bedroom family rental homes. Thirty units will be market‑rate, while 108 will serve families earning 30–60% of the area median income. Plans also include 3,000 square feet of retail **** e and supportive services from the Southern Nevada Regional Housing Authority. Brinshore Development and SNRHA are co‑developers, Metcalf Builders is handling construction, and Enterprise Community Partners is providing $21.7 million in tax credit equity. HUD awarded a $53 million Choice Neighborhoods Grant, and construction began in April 2026.
Western Alliance has financed similar projects in Reno and Las Vegas. However, on July 2, Jefferies Financial (NYSE:JEF) filed suit alleging the bank unlawfully froze a $25 million account tied to Point Bonita Capital, sparking a legal dispute over losses linked to First Brands Group.
Western Alliance Bancorporation (NYSE:WAL), the holding company for Western Alliance Bank, offers a range of commercial and consumer banking services across Arizona, California, and Nevada.

The Islanders and NHL offseason news has generally slowed to a crawl, but their former captain had his formal introduction to Salt Lake City media, and we have salary arbitration dates for those who’ve filed around the league.
So there’s that.
7 Things About: Get to know new depth signing Matthew Kessel, who’s 6’3” but doesn’t come off as a big defenseman, really. [Isles]
Anders Lee and Vincent Trocheck are both happy to be on the same side in Utah instead of facing each other in New York. [Newsday | Post]
I know you’re on pins and needles, Alex Jefferies’ salary arbitration date is set for July 30. [Puck Pedia]

Boston Scientific Corporation (NYSE:BSX) is one of the 10 Best Stocks to Buy in 2026 According to Billionaire D.E. Shaw.
Boston Scientific Corporation (NYSE:BSX) is one of the largest medical device companies in America. Its shares are down by 56% over the past year and by 52% year-to-date. Jefferies was out with a devastating note about the firm as it slashed the share price target to $67 from $100 and kept a Buy rating on the stock. Jefferies commented that a major dip in its US Watchman sales growth forecast to 5% from 14% plaed a major role in its coverage for Boston Scientific Corporation (NYSE:BSX). The Watchman is a heart implant used to prevent strokes and blood clots in people with heart valve problems. Jefferies outlined that it was wary about the market adoption of the Watchman FLX device.
Earlier in the month, Bank of America had reduced Boston Scientific Corporation (NYSE:BSX)'s share price target to $61 from $68 and kept a Buy rating on the stock. A lower utilization for the firm's devices played a role in BofA's coverage. Earlier in the year, Boston Scientific Corporation (NYSE:BSX) made a move into the aortic stenosis market as it invested $1.5 billion in MiRus LLC in order to secure rights to the target's TAVR system.
While we acknowledge the risk and potential of BSX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BSX and that has 10,000% upside potential, check out our report about the cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Broadcom Inc. (NASDAQ:AVGO) is one of the 10 Best Stocks to Buy in 2026 According to Billionaire D.E. Shaw.
Semiconductor designer Broadcom Inc. (NASDAQ:AVGO)'s shares have been quite volatile over the past couple of days. While they are up by 15% year-to-date, they lost 12% between June 18th and July 2nd, only to gain 11% since then. On June 30th, Jefferies discussed Broadcom Inc. (NASDAQ:AVGO) as it reiterated a Buy rating and a $550 share price target. It discussed the chip company's AI business and outlined that Broadcom Inc. (NASDAQ:AVGO) was benefiting from increased visibility into future earnings. Jefferies added that the firm's Tensor AI chip business with Google was also doing well.
Broadcom Inc. (NASDAQ:AVGO)'s AI chip demand was at the center of a 19.5% share price drop between June 3rd and 5th as it failed to raise its revenue guidance for the products. Erste Group downgraded the shares to Hold from Buy on July 7th and outlined that it believed that the current share price levels reflect most of the firm's valuation.
For illustration purposes only. Photo from Pixabay/Pexels
Carillon Eagle Growth fund discussed Broadcom Inc. (NASDAQ:AVGO) in its Q1 2026 investor letter:

We recently published Jim Cramer Insisted Recent AI Chip Selloff Wasn't A Bottom & Discussed These 17 Stocks. The Boeing Company (NYSE:BA) is one of the stocks discussed by Jim Cramer.
Aerospace giant The Boeing Company (NYSE:BA)'s shares are up by 4.2% over the past year and are flat year-to-date. Jefferies and Wells Fargo discussed the firm in early June. The former reiterated a $295 share price target and a Buy rating on the stock, while the latter kept an Overweight rating and a $250 share price target. Cramer has been one of The Boeing Company (NYSE:BA)'s strongest supporters and has kept the faith in the firm during its tumultuous times. In 2025, he was one of the first to suggest that the company's cash flows under CEO Kelly Ortberg might be improving after it had suffered from production slowdowns following the FAA's orders. The CNBC TV host has praised Ortberg on multiple occasions, and this time, he commented on The Boeing Company (NYSE:BA)'s recent share price performance:
"Impressive catch-up move by Boeing after big run in airlines. Honeywell Aerospace starting its take-off.
"With Boeing and GE Aerospace taking off it might be worth it to buy some HONA which reversed after a very good run. All three are pure play aero but HONA has the most upside imo"
Jirat Teparaksa/Shutterstock.com

July 10, 2026 6:15 am ET
Listen
(3 min)
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.
1622 GMT – The failure of Wainua, a heart disease drug developed by AstraZeneca and Ionis, to meet a primary endpoint in a phase 3 trial is a positive for both BridgeBio Pharma and Alnylam Pharmaceuticals, according to Jefferies **** ysts. For BridgeBio, the news is a potential clearing event for its Attruby drug, an oral stabilizer that addresses the same rare heart disease known as transthyretin amyloid cardiomyopathy. It’s also a headwind for Alnylam, whose Amvuttra treatment will remain the only gene silencer for ATTR-CM, the **** ysts write, although long-term questions remain for the company’s next-generation silencer. Alnylam stock is up 2.4%, erasing some gains after opening up 16%. BridgeBio shares gain 15%. (elias.schisgallwsj.com)

Broadcom Inc. (NASDAQ:AVGO) is one of the top stocks to buy according to Whale Rock Capital Management. On June 30, Jefferies ***** yst Blayne Curtis reiterated his Buy rating and $550 price target on Broadcom Inc. (NASDAQ:AVGO). The ***** yst cited an improving outlook for the company's AI chip business.
A key pillar of Curtis' thesis is Broadcom's improving visibility into FY2028 earnings. In fact, Jefferies ran a scenario ***** ysis that points to earnings per share of between $30 and $40 for that year, which translates into a valuation multiple of roughly 10 times earnings.
Curtis also pointed to an on-track roadmap for Broadcom's custom Tensor Processing Units, the AI chips it co-designs with Google. He noted that this partnership now extends through 2031 under a long-term agreement that guarantees minimum revenue and offers potential upside of more than $500 billion over that period.
Beyond Google, Jefferies highlighted a broadening customer base for Broadcom's application-specific integrated circuits (ASICs). These are the custom chips built for individual AI customers. According to the ***** yst, the broadening customer is an encouraging sign that the company is diversifying away from reliance on a single buyer. One example of such diversification is Broadcom's new partnership with OpenAI, through which the two companies unveiled Jalapeno. This is OpenAI's first custom AI accelerator chip designed specifically for running large language model inference workloads.
Broadcom Inc. (NASDAQ:AVGO) is a semiconductor and infrastructure software company. It designs, develops, and supplies semiconductor devices and software solutions, including networking connectivity products, wireless device connectivity components, server and storage system solutions, and broadband access technologies.

TG Therapeutics, Inc. (NASDAQ:TGTX) is one of the 10 Best Performing American Stocks in June 2026.
On July 6, 2026, TG Therapeutics, Inc. (NASDAQ:TGTX) announced the initiation of a Phase 2 clinical trial evaluating Briumvi in adults with treatment-resistant schizophrenia. The open-label study is designed to evaluate the efficacy and safety of Briumvi in approximately 60 adults with schizophrenia who continue to experience significant symptoms despite standard-of-care antipsychotic treatment.
On June 23, Jefferies raised the firm's price target on TG Therapeutics to $83 from $57 and kept a Buy rating on the shares. Jefferies said the Street "still underappreciates the significance" of Phase 1 subcutaneous Briumvi pharmacokinetic data as predictive of a Phase 3 outcome expected by year-end 2026 to early 2027. Jefferies also updated its model to be more bullish on the subcutaneous opportunity.
On June 9, TG Therapeutics announced topline Phase 1 data for Briumvi in patients with myasthenia gravis and the initiation of a Phase 2 trial evaluating Briumvi as maintenance therapy after induction with efgartigimod. At Week 24, 82% of patients achieved the Minimal Clinically Important Difference in MG-ADL, with a median time to MCID of 30 days, while mean MG-ADL improvement was 4.6 points. The Phase 2 trial is expected to enroll approximately 120 patients, with time to clinical worsening as the primary endpoint.
TG Therapeutics, Inc. (NASDAQ:TGTX) focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.

IREN Ltd (NASDAQ:IREN) is one of the top 10 AI stocks that will skyrocket.
On June 29, IREN Ltd (NASDAQ:IREN) disclosed that it has been included in the Russell 1000 Index after the recent reconstitution of FTSE Russell Indexes. The inclusion became effective at the close of play on June 26.
Addition to the Russell 1000 Index, which is used as a performance benchmark for large-cap stocks, represents a key milestone for the company. It comes after persistent expansion of its customer base, as well as operations across the United States.
Back on June 18, Jonathan Petersen of Jefferies initiated coverage of the stock with a target price of $79, implying almost 73% upside for investors. The ***** yst ***** igned a Buy rating to the stock based on its vertically integrated, GPU-cloud approach.
Peterson reflected favorably on the company's lucrative and sizeable pipeline of powered land. He acknowledged the company's strategic pivot that has earned it a unique spot within the broader AI infrastructure segment.